The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study
Open accessAbstract
Objective: To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality. Design: Population based cohort study using a prevalent new-user design, emulating a trial. Setting: UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases. Participants: Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second included 8942 patients who started SGLT-2 inhibitors and added on GLP-1 receptor agonists. Combination users were matched, in a 1:1 ratio, to patients prescribed the same background drug, duration of background drug, and time conditional propensity score. Main outcome measures: Cox proportional hazards models were fitted to estimate the hazard ratios and 95% confidence intervals of major adverse cardiovascular events and serious renal events, separately, comparing the GLP-1 receptor agonist-SGLT-2 inhibitor combination with the background drug, either GLP-1 receptor agonists or SGLT-2 inhibitors, depending on the cohort. Secondary outcomes included associations with the individual components of major adverse cardiovascular events (myocardial infarction, ischaemic stroke, cardiovascular mortality), heart failure, and all cause mortality. Results: Compared with GLP-1 receptor agonists, the SGLT-2 inhibitor-GLP-1 receptor agonist combination was associated with a 30% lower risk of major adverse cardiovascular events (7.0 v 10.3 events per 1000 person years; hazard ratio 0.70, 95% confidence interval 0.49 to 0.99) and a 57% lower risk of serious renal events (2.0 v 4.6 events per 1000 person years; hazard ratio 0.43, 0.23 to 0.80). Compared with SGLT-2 inhibitors, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 29% lower risk of major adverse cardiovascular events (7.6 v 10.7 events per 1000 person years; hazard ratio 0.71, 0.52 to 0.98), whereas serious renal events generated a wide confidence interval (1.4 v 2.0 events per 1000 person years; hazard ratio 0.67, 0.32 to 1.41). Secondary outcomes generated similar results but with wider confidence intervals. Conclusions: In this cohort study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse cardiovascular events and serious renal events compared with either drug class alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The addition of a GLP-1 RA on top of SGLT2 inhibitor treatment was associated with a 30% lower risk of major adverse cardiovascular events and 57% lower risk of serious kidney events compared with GLP-1 RA therapy alone after a median follow-up of 9 months.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [146]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The addition of an SGLT2 inhibitor on top of GLP-1 RA was associated with a 29% lower risk of major adverse cardiovascular events compared with SGLT2 inhibitor alone.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [146]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When stratified based on history of kidney disease, the use of combination treatment by individuals with a history of kidney disease was associated with a lower risk of major adverse cardiovascular events compared with those without kidney disease (146).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [146]
The cited source says what the claim attributes to it.
In the citing paper
“The authors concluded that the combination of both drug classes was associated with a lower risk of MACE and serious kidney disease events compared with either drug class alone.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Multiple imputation by chained equations: what is it and how does it work?
Azur, M. J., Stuart, E. A., Frangakis, C., & Leaf, P. J. (2011) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.329 · Cited by 3,542
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Research works printed but not linked: 1
- Rubin DB . Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons, 2004.
Cited by
Sorted by citations
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200
Advances and challenges in kidney fibrosis therapeutics
Abbad, L., Estève, E., & Chatziantoniou, C. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00934-5 · Cited by 133
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 105
Treatment of chronic kidney disease in older populations
Kishi, S., Kadoya, H., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00854-w · Cited by 69
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 54
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes
Chaiyakunapruk, N., Tan, X., Liang, Y. M., Guevarra, M., Xie, L., & CHENG, A. Y. Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02737-1 · Cited by 44
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 38
Agarwal, A., Mustafa, R. A., Manja, V., Agoritsas, T., Macdonald, H., Li, S., Foroutan, F., Rayner, D. G., Rodríguez‐Gutiérrez, R., Åsvold, B. O., et al. (2025) · BMJ · doi:10.1136/bmj-2024-082071 · Cited by 28
Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes
Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16077 · Cited by 29
Shokravi, A., Seth, J., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02900-8 · Cited by 32
Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update
Geng, J., Ma, S., Tang, H. R., & Zhang, C. (2025) · Biomedicines · doi:10.3390/biomedicines13061424 · Cited by 26
Colombijn, J. M. T., de Leijer, J. F., Visseren, F. L. J., Verhaar, M. C., van Raalte, D. H., Sattar, N. A., Vernooij, R. W. M., & van Sloten, T. T. (2025) · Diabetologia · doi:10.1007/s00125-025-06565-6 · Cited by 33
Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
MacIsaac, R. J., Trevella, P., & Ekinci, E. I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13609 · Cited by 27
Liu, T., Fan, Z., Li, Y., Xiao, B., & Chang, H. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133229 · Cited by 23
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 28
Scheen, A. J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101594 · Cited by 20
Yepes, C. A., Cardenas-Moreno, I. C., Daza-Arnedo, R., Fériz, K., Yama-Mosquera, E., Rincón, A. R., Castillo, G. A., Suarez-Rodriguez, A. F., Carreño-Jiménez, J., & Builes-Montaño, C. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01722-x · Cited by 24
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 24
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 24
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Epelde, F. (2024) · Medicina · doi:10.3390/medicina60121986 · Cited by 18
Sridharan, K., & Sivaramakrishnan, G. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01730-8 · Cited by 21
The interplay between heart failure and chronic kidney disease
Lala, A., Levin, A., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16371 · Cited by 18
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes
Mendonça, L., Moura, H., Castro‐Chaves, P., Neves, J. S., & Ferreira, J. P. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000584 · Cited by 16
Jhu, J., Fang, Y., Huang, C., Liou, H., Chen, M., & Tsai, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14361 · Cited by 17
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 17
Mann, J. F. E., Marx, N., Deanfield, J. E., Emerson, S. S., Inzucchi, S. E., McGuire, D. K., Mulvagh, S. L., Pop-Busui, R., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1080 · Cited by 24
Antidiabetic Treatment and Prevention of Ischemic Stroke: A Systematic Review
Prentza, V., Pavlidis, G., Ikonomidis, I., Pililis, S., Lampsas, S., Kountouri, A., Pliouta, L., Korakas, E., Thymis, J., Palaiodimou, L., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195786 · Cited by 14
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 16
Feng, Y., Zhang, Y., Gao, F., Liu, M., & Luo, Y. (2024) · Hereditas · doi:10.1186/s41065-024-00345-9 · Cited by 12
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Gonzales-Uribe, A., Ruiz-Cortez, R., Silva, N. C., Olivero, L. J., Agarwal, R., Castillo, S. A., Garcia-Geng, A., Lyu, X., Mendoza‐Quispe, D., Becerra-Gonzales, V. G., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02710-8 · Cited by 14
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 16
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 10
McCarron, É. P., Chinnadurai, R., Meyer, J., Anderson, T., Stępień, K. M., Sharma, R., Woolfson, P. I., & Jovanović, A. (2025) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2025.101229 · Cited by 10
Neuroimmune Mechanisms in Alcohol Use Disorder: Microglial Modulation and Therapeutic Horizons
Ye, J.-H., Zuo, W., Chaudhry, F. A., & Chinn, L. (2025) · Psychoactives · doi:10.3390/psychoactives4030033 · Cited by 10
Blum, M. F., Mehta, S., Surapaneni, A., Carrero, J. J., Zhang, D. “., Inker, L. A., Horwitz, L. I., Blecker, S., Shin, J., & Grams, M. E. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000902 · Cited by 9
Diabetes and Heart Failure: A Literature Review, Reflection and Outlook
Li, X., Zhou, X., & Gao, L. (2024) · Biomedicines · doi:10.3390/biomedicines12071572 · Cited by 10
Wu, Y. (2024) · American Journal of Translational Research · doi:10.62347/mcee4840 · Cited by 8
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 9
Wang, M., & Zuo, L. (2025) · Cardiorenal Medicine · doi:10.1159/000545622 · Cited by 9
Chaudhry, A., Thompson, D. M., & Chanoine, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70240 · Cited by 8
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 9
Dong, H., Chang, L., Tian, T., Shi, R., Yu, K., Wang, C., Liu, Z., Jin, Q., Wang, J., He, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724965 · Cited by 8
Sinclair, A. J., Sequiera, I., & Abdelhafiz, A. H. (2025) · Metabolites · doi:10.3390/metabo15060381 · Cited by 7
Fakih, W., Mroueh, A., Kikuchi, S., Marzak, H., Amissi, S., Gong, D.-S., Kerth, S., Kindo, M. J., Mommerot, A., Pieper, M. P., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101587 · Cited by 6
Empagliflozin: Primus Inter Pares Among Sodium–Glucose Cotransporter-2 Inhibitors?
Biondi‐Zoccai, G., Frati, G., Peruzzi, M., & Booz, G. W. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001605 · Cited by 5
Zhu, J., Wilding, J. P. H., & Gu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i10.2135 · Cited by 8
Obesity Management for Patients with Coronary Artery Disease and Heart Failure
Syed, A. A., Adam, S., Miller, C., & Alkhaffaf, B. H. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.12.006 · Cited by 6
Mahmoud, A., Kamel, I. S., Awad, K., Farina, J., Ibrahim, R., Abdelnabi, M. H., Allam, M., Pham, H. N., Rosenthal, J., Steidley, E. D., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133567 · Cited by 5
Cancer therapy–induced cardiac metabolic reprogramming: A new frontier in cardio-oncology
Lang, Z., Zhao, J., Dong, K., Zhao, Y., Bai, L., Cong, Q., Chen, C., Wang, Y., Tang, J., & Bai, M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115397 · Cited by 4
Pham, H. N., Ibrahim, R., Abdelnabi, M. H., Bcharah, G., Mahmoud, A., Allam, M., Farina, J., Lee, J. Z., Singh, A., Ayoub, C., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf135 · Cited by 6
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 5
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
Choi, J., Mitchell, G., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000949 · Cited by 6
Hösli, P., Renström, F., Laimer, M. W., Cavelti‐Weder, C., Gastaldi, G., Lehmann, R., & Brändle, M. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004108 · Cited by 4
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Chen, Y. (2025) · medRxiv · doi:10.1101/2025.06.03.25328908 · Cited by 4
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 7
Yan, W., Wang, D., Zhang, X., & Xuan, C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5652 · Cited by 3
Abdelhafiz, A. H., Siqueira, I., & Sinclair, A. J. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109193 · Cited by 3
Economos, H., & MacIsaac, R. J. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.109457 · Cited by 4
Miao, Y., He, P., Wang, D.-Y., Yan, L., Cao, H., & Shao, F.-M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.112867 · Cited by 3
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 4
Gliozzi, M., Coppoletta, A. R., Cardamone, A., Carresi, C., Mollace, R., Musolino, V., & Mollace, V. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107744 · Cited by 3
Kim, Y. H., Her, A., Rha, S., Choi, C. U., Choi, B. G., Park, S., Kang, D. O., Hyun, S. J., Cho, J. R., Park, J. Y., et al. (2024) · Cardiology Journal · doi:10.5603/cj.97842 · Cited by 3
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 3
Hsu, C., Hsu, C., fang, X., Yen, F., & Leong, P. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70199 · Cited by 3
Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00518-6 · Cited by 2
Joubert, M., Ducheix, S., Prieur, X., Cariou, B., & Manrique, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70012 · Cited by 2
Yau, K., Ray, J. G., Jeyakumar, N., Luo, B., Abdullah, S. S., Dixon, S. N., Wing, S. L., Clemens, K. K., Castrillon-Ramirez, F., Udell, J. A., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.09.010 · Cited by 2
Maier, G. A., Hennig, B., Rathmann, W., & Kuss, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70523 · Cited by 2
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 3
Management of salt-sensitive hypertension in clinical settings: how should we approach it?
Todua, I. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.003 · Cited by 2
Stamouli, E., Trakatelli, C., Sarigianni, M., Kitsios, K., & Kotsis, V. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03239-4 · Cited by 3
Mann, J. F. E., Badve, S. V., Baeres, F. M. M., Belmar, N., Brown‐Frandsen, K., Buse, J. B., Colhoun, H. M., Deanfield, J. E., Engelmann, M. D. M., Hovingh, G. K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00134-8 · Cited by 5
Henry, P., Jacqueminet, S., Lemesle, G., Prévost, G., Boccara, Cosson, E., Puymirat, É., Angoulvant, D., Roubille, F., Kownator, S., et al. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.02.012 · Cited by 2
Khan, H. U., Akhtar, B., Singla, B., Mughal, H. M. F., Hamid, A., Khan, Z. U., Ismail, S., Sana, M., & Khaliq, M. (2025) · Cureus · doi:10.7759/cureus.84137 · Cited by 2
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
Htoo, P. T., Najafzadeh, M., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Glynn, R. J., Schmedt, N., Déruaz‐Luyet, A., Koeneman, L., Paik, J. M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0270 · Cited by 3
Diabetic kidney disease—Recent updates
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13612 · Cited by 2
Henry, P., Jacqueminet, S., Lemesle, G., Prévost, G., Boccara, F., Cosson, E., Puymirat, É., Angoulvant, D., Roubille, F., Kownator, S., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101645 · Cited by 1
Sue, Y., Lu, D.-E., Chang, T.-I., Chen, C.-Y., Chen, C., Hsu, S., Chu, Y.-L., Huang, N.-J., Chen, T.-H., Lin, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124287 · Cited by 1
Islam, T., & Uddin, M. N. (2025) · EMJ Diabetes · doi:10.33590/emjdiabet/rkyo7834 · Cited by 1
Reule, S. A., Pickthorn, S., Drake, T., Ishani, A., & Foley, R. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.12.001 · Cited by 1
Jansz, T. T., McGovern, A. P., Young, K., Dinsdale, M. M., Cardoso, P., Shields, B. M., Hattersley, A. T., Jones, A. G., Pearson, E. R., Bingham, C., et al. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100139 · Cited by 1
Wu, C., Shah, B. R., Ezekowitz, J. A., Sharma, A., Wang, T., Wu, C. F., Liu, P. P., Edwards, J. D., & Swardfager, W. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag031 · Cited by 1
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
Estler, B., Fröhlich, H., Täger, T., Frey, N., & Frankenstein, L. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01621-4 · Cited by 1
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 1
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Khademi, R., & Shoar, S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00319-y · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Raja, S. G. (2025) · British journal of healthcare and medical research · doi:10.14738/bjhmr.1202.18663 · Cited by 1
Kombinierte Gabe von Antihyperglykämika verringert kardiorenale Risiken bei T2D
Lellis, M. A. D. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2323-3932
The Burden of Heart Failure in the Obese Patient
Jolobe, O. M. P. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.05.019
Yan, W., Wang, D., Zhang, X., & Xuan, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619957
Not all carbs are bad for the kidney
Gusella, G. L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.006
Communiqué. Diagnostic précoce et traitements préventifs de la progression de la fibrose rénale
de médecine, A. N. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.01.006
Jeter, A. F., Melton, B. L., & Newell, B. J. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.97
Emulating randomized trials: treading carefully and pushing the limits
Renoux, C., & Suissa, S. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf023
Self-citationMoreno, D. M., López, G. P., Walther, L. A. Á.-S., Rueda-Camino, J. A., Martín‐Vallejo, J., & Albarrán, O. G. (2025) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251323831
Metadata
- Authors
- Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L.
- Affiliations
- University of Birmingham (GB)
- Hebrew University of Jerusalem (IL)
- Jewish General Hospital (CA)
- Brigham and Women's Hospital (US)
- Corresponding author
- Azoulay, Laurent
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2024-04-25
- Volume
- 385
- Pages
- e078242
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC11043905
- OpenAlex
- W4395446333
- Cited by
- 151
- References
- 43
- Citations by year
- 2026: 65 · 2025: 60 · 2024: 26
- FWCI
- 49.73
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, SGLT2 inhibitors, combination therapy, type 2 diabetes, major adverse cardiovascular events, heart failure, all-cause mortality, cardiovascular mortality, myocardial infarction, ischemic stroke, drug safety, propensity score matching, new-user cohort, Clinical Practice Research Datalink, Hospital Episode Statistics, Office for National Statistics
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, United Kingdom, Humans, Hypoglycemic Agents, Male, Middle Aged, Cohort Studies, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
